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Morphinans play an important role among therapeuti-
cally valuable opioids. They include powerful pain reliev-
ing agents such as naturally occurring alkaloids (e.g.
morphine, codeine), semisynthetic derivatives (e.g. oxy-
codone, oxymorphone, buprenorphine), and synthetic
analogues (e.g. levorphanol, butorphanol). These opioid
drugs produce their biological actions through three
receptor types, μ, δ and κ, belonging to the family of seven
transmembrane G protein-coupled receptors. All three
opioid receptors are located in the central and peripheral
nervous systems of many species including human. Mor-
phine and related opioids currently prescribed as potent
analgesics for the treatment of severe pain produce their
analgesic activity primarily through their agonist action at
μ opioid receptors, which is the main receptor type tar-
geted for pharmacotherapy of pain. Despite their wide-
spread use, opioid drugs have a number of severe side
effects including respiratory depression, emesis, sedation,
constipation, tolerance, and physical dependence. Conse-
quently, a great deal of effort was spent trying to develop
safer, more efficacious and non-addicting compounds,
with the goal of an improved therapeutic index. Optimal
physicochemical properties are often an important con-
sideration for the development of bioactive molecules as
therapeutic agents. Therefore, a significant aim in medici-
nal chemistry research and drug development is to predict
the behavior of targeted molecules based on their physic-
ochemical features. This task, however, cannot be accom-
plished without correlating and understanding the
differences in the physicochemical and pharmacological
properties of existing opioid morphinans. Toward this
goal, we performed a comparative study on physicochem-
ical properties and biological activities of well-known opi-
oid morphinans such as the naturally occurring alkaloid
morphine, and semisynthetic analogues e.g. oxymor-
phone. Besides the classical and clinically relevant opioid
analgesics, synthetic morphinans developed by our group
were included in the study, the 14-O-methyl derivative of
oxymorphone and its 5-methyl substituted analogue, 14-
methoxymetopon. The major physicochemical parame-
ters (pKa, logP and logD) have been experimentally deter-
mined using a Sirius PCA200/Cheqsol Instrument. In vitro
binding affinities and selectivities to opioid receptors
were determined in rodent brain membranes using bind-
ing assays. Analgesic potencies were evaluated after subcu-
taneous administration to mice using tail-flick and hot-
plate tests. The structure-activity relationship observa-
tions, combining physicochemical and biological data,
will be discussed. Altogether, the present study indicate
that specific structural elements are required to confer
high affinity/selectivity for μ opioid receptors and potent
agonist and analgesic activity in the morphinan class of
opioids, and are important in drug development.
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